Authors: Andrea Tamas Andras Javorhazy Dora Reglodi Donat Peter Sarlos Daniel Banyai David Semjen Jozsef Nemeth Beata Lelesz Daniel Balazs Fulop Zalan Szanto
Publish Date: 2015/10/10
Volume: 59, Issue: 2, Pages: 177-183
Abstract
Numerous studies investigated the localization of pituitary adenylate cyclaseactivating polypeptide PACAP and its receptors in different tumors and described the effects of analogs on tumor growth to show its potential role in oncogenesis Recently our research group has found significantly lower levels of PACAP27like immunorreactivity LI and PACAP38LI in different human samples of primary small cell lung cancer and colon cancer compared to normal healthy tissues There are only few human studies showing the presence of PACAP and its receptors in urogenital tumors therefore the aim of the present study was to compare PACAPLI in different healthy and pathological human samples from urogenital organs kidney urinary bladder prostate testis with radioimmunoassay RIA method Similar to our earlier observations the PACAP27LI was significantly lower compared to PACAP38LI in all samples We did not find significant alterations in PACAPLI between healthy and tumoral samples from the urinary bladder and testis On the other hand we found significantly lower PACAP38LI level in kidney tumors compared with healthy tissue samples and we showed higher PACAP27LI in prostatic cancer compared to samples from benign prostatic hyperplasia These data indicate that PACAP levels of different tissue samples are altered under pathological conditions suggesting a potential role of PACAP in the development of different urogenital tumorsThis study was supported by the following grants OTKA K104984 Arimura Foundation TÁMOP411C13/1/KONV20140001 TÁMOP422B15/KONV20150011 TÁMOP 424A/211120120001 “National Excellence Program” Janos Bolyai Research Scholarship of Hungarian Academy of Sciences MTAPTE “Lendulet” Program The authors also thank all the volunteers
Keywords: